Clinical Trials Browser

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02334748 2020-05-19

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Phase 3 Completed

31 enrolled 7 charts

Rheumatoid Arthritis, Systemic Juvenile, Bronchiolitis Obliterans Syndrome, Arthritis, Juvenile, Arthralgia, Mevalonate Kinase Deficiency, Cryopyrin-Associated Periodic Syndromes

NCT02911857 2018-08-20

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Phase 3 Completed

4 enrolled 7 charts

Periodic Fevers Syndrome

Clinical Trials

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

SPARC-1

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Study of Canakinumab in Patients With Myelofibrosis

CANOPY-1

Evaluation of Canakinumab in High-Risk Former-Smokers

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

CHORUS

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

PanCAN-SR1

Canopy-A

CANOPY-N

PLATforM

CANOPY-2

CANAL

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes